These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34486009)

  • 1. Cell-specific activation of gemcitabine by endogenous H
    Maiti M; Yoon SA; Cha Y; Athul KK; Bhuniya S; Lee MH
    Chem Commun (Camb); 2021 Sep; 57(75):9614-9617. PubMed ID: 34486009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
    Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
    J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
    Wang Q; Zhu X; Wu Z; Sun T; Huang W; Wang Z; Ding X; Jiang C; Li F
    J Mater Chem B; 2020 Mar; 8(12):2410-2417. PubMed ID: 32100811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereocomplex Prodrugs of Oligo(lactic acid)
    Tam YT; Huang C; Poellmann M; Kwon GS
    ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-stimuli responsive polymeric prodrug micelles for combined chemotherapy and photodynamic therapy.
    Hu C; Zhuang W; Yu T; Chen L; Liang Z; Li G; Wang Y
    J Mater Chem B; 2020 Jun; 8(24):5267-5279. PubMed ID: 32441291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy.
    Chen L; Zhuang W; Hu C; Yu T; Su X; Liang Z; Li G; Wang Y
    J Mater Chem B; 2020 Jul; 8(26):5645-5654. PubMed ID: 32538389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Activation of a Prodrug by Thioredoxin Reductase Providing a Strategy to Target Cancer Cells.
    Li X; Hou Y; Meng X; Ge C; Ma H; Li J; Fang J
    Angew Chem Int Ed Engl; 2018 May; 57(21):6141-6145. PubMed ID: 29582524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
    Alexander RL; Greene BT; Torti SV; Kucera GL
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine Integrated Nano-Prodrug Carrier System.
    Hamsici S; Sardan Ekiz M; Cinar Ciftci G; Tekinay AB; Guler MO
    Bioconjug Chem; 2017 May; 28(5):1491-1498. PubMed ID: 28441471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
    Abd Al-Jabbar S; Atiroğlu V; Hameed RM; Guney Eskiler G; Atiroğlu A; Deveci Ozkan A; Özacar M
    Bioorg Chem; 2022 Jan; 118():105467. PubMed ID: 34781115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
    Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
    Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine.
    Weiss JT; Dawson JC; Fraser C; Rybski W; Torres-Sánchez C; Bradley M; Patton EE; Carragher NO; Unciti-Broceta A
    J Med Chem; 2014 Jun; 57(12):5395-404. PubMed ID: 24867590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled drug release from polyelectrolyte-drug conjugate nanoparticles.
    Catarata R; Azim N; Bhattacharya S; Zhai L
    J Mater Chem B; 2020 Apr; 8(14):2887-2894. PubMed ID: 32191246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
    Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
    J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomized tumor-microenvironment-active NIR fluorescent prodrug for ensuring synchronous occurrences of drug release and fluorescence tracing.
    Li Q; Cao J; Wang Q; Zhang J; Zhu S; Guo Z; Zhu WH
    J Mater Chem B; 2019 Mar; 7(9):1503-1509. PubMed ID: 32255021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.